News & Analysis · 2684 stories

News & analysis, rated.

Breaking AI developments, in-depth guides, real-world case studies, and analysis — each one rated so you know what matters.

Verified
June 9, 2026 · 3 min

Roche pays $2.3B for blood cancer drug that degrades BTK protein

Roche and Nurix licensed bexobrutideg, an oral BTK degrader, in a deal worth up to $2.3 billion. The drug targets B-cell malignancies and enters Phase III trials this summer.

Verified
June 9, 2026 · 2 min

Incyte pays $2bn for VGA039, a monthly shot for bleeding disorders

Incyte will spend up to $2 billion to acquire Vega Therapeutics and its late-stage von Willebrand disease candidate. The drug could displace frequent IV infusions with once-monthly dosing.

Verified
June 9, 2026 · 3 min

90% of blockbuster drugs lack biosimilar competitors—why pricing kills the pipeline

A 2025 IQVIA analysis found 90% of biologics losing patent protection this decade have no biosimilar in development. Samsung Bioepis exec explains why: broken economics, not broken science.

Verified
June 9, 2026 · 3 min

Pfizer's Hympavzi Now Covers Kids 6+ With Haemophilia A or B

FDA expanded Hympavzi approval to children aged 6–11 and adolescents 12+ with inhibitors. The once-weekly injection showed 93% bleeding reduction versus on-demand IV treatment in Phase III trials.

Verified
June 9, 2026 · 3 min

J&J buys Firefly Bio for $1B to target KRAS cancers

Johnson & Johnson is acquiring Firefly Bio for $1 billion to add its Firelink degrader-antibody conjugate platform to its oncology pipeline. The deal targets KRAS-driven solid tumors, where treatment options remain limited.

Verified
June 9, 2026 · 3 min

Spain's pharma sector pulls €1.5B in annual R&D as multinationals expand

Spain ranks third in EU scientific output and leads Europe in clinical trials approved annually. Merck, Eli Lilly, Bayer, and a dozen other pharma giants are investing billions. Here's why the country is becoming a magnet for life science capital.

Incremental
June 9, 2026 · 3 min

CRISPR Targets p53 Mutations in Half of All Cancers

Jennifer Doudna's lab engineered a CRISPR system that kills cancer cells by recognizing mutant p53 mRNA with single-nucleotide precision. Mouse studies show the approach works on lung and liver tumors.

Incremental
June 9, 2026 · 3 min

Lawyers Can Now Catch AI-Invented Case Citations Before Filing

BrentWorks launched CiteSentinel to scan legal briefs for fabricated cases, statutes, and authorities before they reach a judge. The tool works on your own drafts, co-counsel submissions, and opposing filings.

Verified
June 9, 2026 · 3 min

Institut Pasteur Funds $17M Chikungunya Vaccine Trial Across Africa

EU-backed ACT-CHIK project will test MV-CHIK vaccine in Rwanda, Kenya, Nigeria, and Senegal while preparing local manufacturing. Here's what the trial covers and why African vaccine sovereignty matters.

Incremental
June 9, 2026 · 3 min

AI designs caffeine-triggered kill switch for CAR T cells

Texas A&M researchers used protein design to turn caffeine into a molecular off-switch for engineered cells. The system could let doctors pause cell therapies without destroying them.

Incremental
June 9, 2026 · 3 min

95% of Detectable HIV in Treated Patients Is Defective RNA

Johns Hopkins researchers found that nearly all persistent viral traces in people on long-term HIV therapy are non-infectious copies. A new diagnostic tool could spare patients unnecessary drug changes and anxiety.

Verified
June 9, 2026 · 3 min

Antibiotic resistance genes found across all world oceans

Italian-led SeA Care project detected resistance genes in over 140 ocean sites across five basins, with highest concentrations near shipping routes and coastal cities. Study suggests oceans function as a global reservoir for land-based pollution.